Castle biosciences announces preliminary fourth quarter and full-year 2023 results

Friendswood, texas--(business wire)--castle biosciences, inc. (nasdaq: cstl), a company improving health through innovative tests that guide patient care, today announced certain unaudited preliminary performance results for the fourth quarter and year ended dec. 31, 2023. “our fourth quarter was the culmination of an exceptional year, where we delivered consistent, strong growth in both revenue and test volume,” said derek maetzold, president and chief executive officer of castle biosciences.
CSTL Ratings Summary
CSTL Quant Ranking